Niacin for Parkinson's disease
- Marissa Seamon,
- ,
- Banabihari Giri,
- ,
- John Morgan,
Open access
Abstract
Parkinson's disease (PD) is a neurodegenerative disease associated with progressive loss of motor function and cognitive decline occurring in 1% of the USA population. There is no cure for PD, and current treatment regimens are directed towards treating symptoms and not treating the underlying cause of the disease. Chronic neuroinflammation is associated with loss of neuronal cells, leading to motor and cognitive decline. Current clinical trials on drugs and nutraceuticals, such as coenzyme Q10 and niacin, are being carried out to delay progression and reduce damage by inflammatory molecules, such as reactive oxygen species and cytokines, in PD patients. In this review, we present available clinical trials and the role of niacin in reducing neuroinflammation in PD.
Publication Information
Output type
Original language
English (US)Pages from-to (Number of pages)
Pages 47-56 (10 pages)Journal (Volume, Issue Number)
Clinical and Experimental Neuroimmunology (Volume 11, Issue 1)Publication milestones
- Accepted/In press - 01/01/2019
- Published - 02/01/2020
Publication status
ISSN
1759-1961Publication IDs
- Scopus: 85077379986
- ORCID: /0000-0002-2706-1300/work/119744956
- ORCID: /0000-0003-0385-3829/work/121881153
